A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003 on ClinicalTrials.gov · last registry update 2024-04-08

An unusually large phase 3: 938 participants, more than double the 424 typical for the stage. The sponsor logged completion for 16 March 2023. Primary outcome, as filed: Percent Change From Baseline in Body Weight. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 938
Started: 2021-03-29
Primary completion: 2023-03-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight

Conditions studied

Type 2 Diabetes · Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.